Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lacosamide - UCB

X
Drug Profile

Lacosamide - UCB

Alternative Names: ADD 234037; Erlosamide; Harkoseride; SPM 927; SPM 929; Vimpat; VIMPATÒ

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Houston
  • Developer Daiichi Sankyo Company; Duke University; UCB
  • Class Acetamides; Analgesics; Antiepileptic drugs; Benzene derivatives; Neuroprotectants; Small molecules
  • Mechanism of Action CRMP2 protein modulators; Glycine gated NMDA receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies; Tonic-clonic epilepsy
  • Phase III Generalised seizures
  • Phase II/III Epilepsy; Neonatal seizures
  • Phase II Seizures
  • No development reported Essential tremor; Fibromyalgia; Osteoarthritis; Pain; Sleep disorders
  • Discontinued Migraine; Neuropathic pain

Most Recent Events

  • 30 Mar 2023 UCB completes the phase III VALUE trial in Generalised seizures (Adjunctive treatment, In adolescents, In children, In adults, In the elderly) in USA, Australia, Brazil, South Korea, Israel, Russia, Turkey, Taiwan, Japan, Mexico, Bulgaria, Belgium, China, Czech Republic, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Russia, Slovakia, Spain (PO) (EudraCT2012-001770-29) (NCT02408549)
  • 18 May 2021 UCB completes a phase II trial in Epilepsy (Adjunctive therapy, In infants, In children and Adolescents) in the Belgium, China, France, Germany, Hungary, Italy, Japan, Mexico, Poland, Ukraine and USA (NCT00938912)
  • 29 Dec 2020 UCB Biopharma initiates enrolment in the long term phase III extention trial for Epilepsy in Hungary and Georgia (NCT04627285)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top